Novo Nordisk, Wegovy
EU regulator backs use of Novo's Wegovy for obesity-related heart condition
The European Medicines Agency backed the use of Novo Nordisk's popular drug Wegovy to help ease heart failure in people with obesity, the Danish drugmaker said on Thursday. This marks the regulator's second backing for a use of Wegovy beyond weight loss and further strengthens Novo's case that the medicine has multiple health benefits.
Novo’s Wegovy Backed by EU Regulator For Obesity-Related Heart Conditions. FDA Could Be Next.
Novo Nordisk’s obesity drug Wegovy is now recommended by EU regulatory authorities for obesity-related heart conditions. Approval in the U.S.–Novo’s biggest market for obesity drugs–by the Food and Drug Administration could be next.
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
Novo Nordisk’s New Obesity Pill Beats Wegovy In Early Trial
Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more rapid weight loss than its popular obesity injection Wegovy.
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
The Pharma Letter5h
Wegovy label should be extended, CHMP recommends
The European Medicines Agency’s (EMA) advisory committee the CHMP has adopted a positive opinion for a label update of Danish ...
Is Wegovy covered by Medicare?
Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...
Lohud.com, Westchester County on MSN3d
Do you want to take Wegovy, Ozempic in New York? Are you taking it now? Tell us your story
Nearly 4.4 million adult New Yorkers, or 30%, have obesity, but access to weight-loss medications varies based on a variety ...
Wegovy, Ozempic may someday be available as monthly injection
A slow-release form of semaglutide could allow people who use Wegovy or Ozempic to get shots once a month, instead of the ...
Everyday Health6d
Wegovy May Reduce the Risk of Death From COVID-19, Study Suggests
A new study found that people taking Wegovy during the pandemic were 33 percent less likely to die of COVID-19.
STAT1d
Pharmalittle: We’re reading about a rare-disease drug bill, compounded Wegovy, and more
So here are some items of interest. Have a great day, everyone. … Hims & Hers Health plans to sell compounded versions of Novo Nordisk’s popular weight loss drug Wegovy to patients in certain ...
Hims & Hers offers compounded Wegovy for $99 a month to select professions
U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...
Novo’s Wegovy Price Tag for Stroke Prevention Is Higher in US
Novo Nordisk A/S’s obesity shot Wegovy also prevents strokes, heart attacks and death. The price of those benefits is far ...